John Libbey Eurotext

European Journal of Dermatology


Development of lichen planus following benralizumab treatment Article à paraître


  • Figure 1
1 Division of Dermatology & Skin Oncology, Chutoen General Medical Center, Kakegawa, Japan
2 Department of Dermatology,
3 Department of Cellular & Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan

Lichen planus (LP) is a disease manifesting with violaceous erythematous papules. In LP, type II interferon (IFN), IFN-γ, has been shown to prime keratinocytes and increase their susceptibility to Tc1-mediated cytotoxic responses through MHC Class I induction, and this process is dependent upon JAK2 and STAT1, but not JAK1 or STAT2 signalling [1, 2]. Involvement of Th17/Tc17 is also postulated [3]. Drugs and hepatitis C virus infection may cause LP [3], and other factors may also skew the T-cell [...]